

Anti-Inflammatory Potential of Musali Species: A Pharmacognostic, Phytochemical and Experimental Review

Rutuja M. Suryawanshi^{*1}, Dr. Amol R. Kshirsagar², Dr. Ravi U. Kurhade³,
Mohini S. Survase⁴, Nishinandan M. Shinde⁵

¹M. Pharm Final Year Student, Department of Pharmacology

²Professor, Department of Pharmacology

³Principal, Department of Pharmaceutics

⁴Assistant Professor, Department of Quality Assurance

⁵Assistant Professor, Department of Pharmaceutics

MDA School of Pharmacy, Kolpa, Latur, Maharashtra

rutujasu55@gmail.com

Abstract: Musali is a traditional herbal drug group that includes botanically distinct species such as *Curculigo orchioidea*, *Chlorophytum borivilianum*, *Asparagus adscendens*, *Chlorophytum tuberosum*, *Chlorophytum arundinaceum* and *Chlorophytum orchidastrum*. The common name creates a practical problem for herbal medicine, because species with different morphology and phytochemistry may not show equivalent anti-inflammatory activity. This review summarizes the pharmacognostic identity, major phytochemical classes, reported anti-inflammatory relevance, experimental models and Quality by Design considerations for comparative Musali evaluation. Literature from the supplied thesis reference set indicates that *C. orchioidea* and *C. borivilianum* have stronger evidence for anti-inflammatory or related pharmacological activity, while other Musali-like species require additional validation. Mechanistically, phenolic glycosides, saponins, flavonoids, sterols and polysaccharides may contribute to antioxidant action, modulation of inflammatory mediators, reduced vascular permeability and tissue protection. The review concludes that botanical authentication, marker-based standardization, controlled experimental design and endpoint-based comparison are essential before Musali species are used interchangeably in anti-inflammatory formulations.

Keywords: Musali; anti-inflammatory; *Curculigo orchioidea*; *Chlorophytum borivilianum*; phytochemistry; Shotha; herbal standardization; QbD

I. INTRODUCTION

Inflammation is a complex protective reaction involving vascular changes, immune-cell movement, mediator release and tissue repair. When excessive, recurrent or poorly regulated, the same process contributes to tissue injury and chronic pathological states [1]. Herbal drugs used for swelling, pain and inflammatory disorders are therefore frequently investigated in experimental models.

The Musali drug group is important in Ayurveda and ethnomedicine because it is associated with strength, nourishment, rejuvenation and tissue support. However, Musali is not one single botanical entity. Multiple plants may be used under Kali Musli, Safed Musli or related trade names, including *Curculigo orchioidea*, *Chlorophytum borivilianum*, *Asparagus adscendens* and other *Chlorophytum* species. This creates a need for species-wise review and standardization [10,11,16,22,23].



This review was prepared from the attached dissertation chapters and reference list to synthesize the anti-inflammatory relevance of selected Musali species, with emphasis on botanical identity, phytochemical plausibility, preclinical evidence, experimental model selection and quality control.




Figure 1. Conceptual framework linking traditional Musali use with acute inflammation evaluation.

II. REVIEW METHODOLOGY

The review is based on the provided thesis chapters covering introduction, literature review, drug profile, Quality by Design, materials and methods, results and references. The included literature focuses on inflammation biology, Ayurvedic Shotha, carrageenan-induced paw edema methodology, pharmacognosy of Musali species, phytochemistry and species-wise anti-inflammatory evidence. The synthesis is narrative and integrative rather than meta-analytic because quantitative effect sizes, extraction methods and endpoints differ across cited sources.

III. BOTANICAL DIVERSITY OF MUSALI

A major theme emerging from the supplied material is that Musali is a pharmacognostic group rather than a single uniform plant. Species identity is therefore the first quality requirement. Without authentication, the observed clinical or experimental response may reflect substitution rather than true inefficacy of the intended drug.

Table 1. Botanical diversity and pharmacognostic interpretation of selected Musali species

Species	Traditional/common relevance	Botanical implication	Review interpretation
Curculigo orchioides	Kali Musli / Black Musli	Hypoxidaceae; root/tuber; phenolic glycoside-rich profile	Best-supported candidate for acute anti-inflammatory evaluation.



Chlorophytum borivillianum	Safed Musli	Asparagaceae; fleshy roots; saponin-rich drug	Moderate evidence for anti-inflammatory, anti-arthritic and supportive effects.
Asparagus adscendens	Shweta/Safed Musli-like plant	Asparagaceae; tuberous roots; adaptogenic and nutritive value	May support inflammation through immunomodulatory and tonic effects; acute anti-edematous evidence remains weaker.
Chlorophytum tuberosum	Safed Musli variant	Asparagaceae; substitute/variant	Requires more marker-based and comparative validation.
Chlorophytum arundinaceum	Safed Musli variant	Asparagaceae; less-studied species	Possible cytokine or immunomodulatory relevance, but limited direct evidence.
Chlorophytum orchidastrum	Fire Flash / ornamental comparator	Asparagaceae; less-established medicinal use	Weakest support as anti-inflammatory substitute; authentication concern.




Figure 2. Species-level differentiation of Musali drugs.

IV. AYURVEDIC AND PHARMACOLOGICAL CONTEXT OF SHOTHA

In Ayurveda, inflammatory swelling is commonly discussed under Shotha or Shopha. Vata may be associated with pain and functional disturbance, Pitta with heat and redness, and Kapha with heaviness and chronic swelling. Modern interpretation can map these features to edema, mediator release, vascular permeability, oxidative stress and tissue infiltration.

The value of integrating Ayurvedic and experimental frameworks is that traditional indications can be evaluated through measurable endpoints without rejecting their clinical meaning. In the case of Musali, the question is not whether all species are useful as tonics, but whether they are equally relevant for acute inflammatory swelling.



V. PHYTOCHEMICAL BASIS OF ANTI-INFLAMMATORY ACTIVITY

Musali species contain diverse phytochemical groups. *C. orchoides* is associated with curculigoside and phenolic glycosides, while *C. borivilianum* is commonly linked with steroidal saponins. Other species contain variable combinations of saponins, flavonoids, polysaccharides, sterols and related secondary metabolites. These compounds may influence inflammatory pathways through antioxidant effects, membrane stabilization, reduction of mediator release and modulation of immune signaling [2,4,8,9,16,20,22,23].

Table 2. Phytochemical classes and expected anti-inflammatory relevance

Phytochemical class	Representative relevance	Probable anti-inflammatory contribution
Phenolic glycosides	Curculigoside-like constituents in <i>C. orchoides</i>	Antioxidant action, reduced oxidative tissue injury, possible mediator modulation.
Saponins	Important in <i>C. borivilianum</i> and several Musali-like roots	Membrane stabilization, immunomodulatory effects and possible reduction of edema.
Flavonoids	Variable distribution across selected species	Free radical scavenging and possible inhibition of inflammatory enzymes.
Sterols and steroidal constituents	Reported in saponin-rich roots	Supportive modulation of inflammatory responses.
Polysaccharides and nutritive components	Common in fleshy/tuberous roots	Tonic and immunological support rather than immediate strong anti-edematous action.




Figure 3. Simplified drug-mechanism map for *Curculigo orchoides* in inflammation.



VI. EVIDENCE FROM INDIVIDUAL MUSALI SPECIES

6.1 *Curculigo orchioides*

Curculigo orchioides has the strongest evidence base among the reviewed Musali species. Experimental reports describe anti-inflammatory and analgesic actions of root/tuber or rhizome fractions, including activity in carrageenan-induced paw edema and chronic inflammatory models [8,9]. Reviews also highlight its broad pharmacological profile and phytochemical richness [16,22,30]. The presence of phenolic glycosides and saponins provides a plausible basis for antioxidant and mediator-modulating effects.

6.2 *Chlorophytum borivilium*

Chlorophytum borivilium is widely used as Safed Musli and has attracted considerable attention due to saponin-rich roots. Literature cited in the dissertation reports anti-inflammatory, anti-arthritis and analgesic activities of ethanol fractions or saponin constituents [2,4,6,7,23]. However, the evidence suggests a supportive or moderate anti-inflammatory role rather than consistent superiority over *C. orchioides* in an acute edema model.

6.3 *Asparagus adscendens* and other Musali-like species

Asparagus adscendens and related Musali-like species may contribute nutritive, adaptogenic or immunomodulatory effects. Their anti-inflammatory role may be indirect, especially through stress-cytokine modulation or antioxidant support [18,19,24]. *Chlorophytum tuberosum* and *C. arundinaceum* require stronger direct anti-inflammatory and marker-standardized studies [25,26,33]. *Chlorophytum orchidastrum* is less established and should not be assumed to be therapeutically interchangeable with medicinal Musali species [27,31].

Table 3. Thematic summary of literature evidence used in the review

Reference focus	Key evidence type	Review use
Inflammation biology and disease relevance [1,3]	General immunological background	Supports need for anti-inflammatory screening.
Carrageenan paw edema model [15]	Classical animal model methodology	Justifies acute edema endpoint.
<i>C. borivilium</i> saponins [2,4,6,7]	Anti-inflammatory/anti-arthritis preclinical evidence	Supports Safed Musli as a comparator species.
<i>C. orchioides</i> fractions and tubers [8,9,16,20,22]	Anti-inflammatory, analgesic and supportive mechanistic evidence	Supports Kali Musli as lead candidate.
<i>Asparagus/Chlorophytum</i> variants [18,24-27,33]	Adaptogenic, immunomodulatory or limited direct evidence	Supports cautious interpretation of variants.

VII. EXPERIMENTAL MODELS AND ENDPOINT INTERPRETATION

The carrageenan-induced paw edema model remains a useful first-line model for acute anti-inflammatory screening. It allows time-course observation of early and late inflammatory phases. However, interpretation should consider vehicle, dose timing, animal variability, paw measurement precision and endpoint-specific limitations. A reduction in paw volume supports anti-edematous activity, but mechanistic confirmation requires cytokine, enzyme, oxidative stress and histological endpoints.






Figure 4. Carrageenan-induced inflammatory phase map.

VIII. QUALITY BY DESIGN IN HERBAL ANTI-INFLAMMATORY STUDIES

QbD is especially relevant in herbal pharmacology because the quality of the output depends on the quality of the starting material and the consistency of each procedure. Critical material attributes include species identity, root maturity, moisture, ash, extractive value and marker content. Critical process parameters include drying, grinding, sieving, storage, dose preparation, gavage, carrageenan injection, paw volume measurement, histology and statistics.

Table 4. QbD elements for reliable Musali anti-inflammatory evaluation

QbD component	Application to Musali studies	Control measure
QTPP	Comparable anti-inflammatory profile of Musali species	Predefined endpoints and ranking criteria.
CQA	Paw volume reliability, histology, safety observations	Calibration, measurement logs and blinded recording.
CMA	Botanical identity, phytochemical profile, moisture/ash	Authentication, voucher specimen and basic phytochemistry.
CPP	Drying, powdering, dosing, carrageenan injection, timing	SOPs, training and documented deviations.
Risk control	Misidentification, dose error, animal variability	Randomization, coded samples and repeated measurements.






Figure 5. Fishbone diagram of QbD variables for herbal anti-inflammatory study.






Figure 6. Handwritten-style QbD control strategy cycle for comparative Musali evaluation.

IX. COMPARATIVE INTERPRETATION AND RESEARCH GAPS

Across the supplied thesis material, the comparative interpretation is that *C. orchioides* is the strongest anti-inflammatory Musali candidate in the acute paw edema model, followed by *C. borivilianum*. Other species show weaker, variable or insufficiently validated activity. This hierarchy supports the position that botanical substitutes must be validated before use in inflammation-focused formulations.

Several gaps remain. Many studies use different extracts, doses, models or endpoints, making direct comparison difficult. Standardized marker quantification is often limited. Chronic inflammation models, cytokine panels, COX/LOX assays, oxidative stress markers, pharmacokinetic observations and dose-response studies are needed to confirm whether acute paw edema findings translate into broader therapeutic relevance.

Another gap is the limited integration of traditional classification with modern outcome-based ranking. Future studies should define the intended use clearly: a species may be valuable as a Rasayana or tonic but less relevant for rapid acute edema suppression. This distinction prevents inappropriate generalization across the Musali group.

Table 5. Evidence strength and future research gaps for selected Musali species

Species	Evidence strength for anti-inflammatory use	Major gap
<i>C. orchioides</i>	Relatively strong preclinical support	Requires marker-based extract standardization and mechanistic assays.
<i>C. borivilianum</i>	Moderate support from saponin-related studies	Needs direct comparison with <i>C. orchioides</i> under identical conditions.
<i>A. adscendens</i>	Supportive/adaptogenic relevance	Needs more acute inflammation and cytokine-based studies.



C. tuberosum	Limited evidence	Needs authentication, extract standardization and dose-response data.
C. arundinaceum	Limited/moderate immunomodulatory indications	Needs direct anti-edematous validation.
C. orchidastrum	Weakest anti-inflammatory support	Should not be substituted without evidence.

X. CONCLUSION

The review concludes that the Musali group should be understood as botanically and pharmacologically diverse. *Curculigo orchioidea* appears to be the most promising candidate for anti-inflammatory evaluation, while *Chlorophytum borivilianum* has moderate supportive evidence. *Asparagus adscendens*, *C. tuberosum*, *C. arundinaceum* and *C. orchidastrum* require stronger validation before they are used interchangeably in inflammation-focused formulations. Future research should integrate pharmacognostic authentication, phytochemical marker standardization, QbD-based experimental control and mechanistic assays to develop scientifically reliable Musali-based anti-inflammatory preparations.

XI. DECLARATIONS

Conflict of interest: The authors should declare any financial or non-financial conflicts.

Funding: [Insert funding details or state "No external funding"].

Author contribution: [Insert contribution statement according to journal guideline].

REFERENCES

1. Agrahari, A. K., et al.. Studies on the anti-inflammatory properties of *Curculigo orchioidea* Gaertn. root tubers. *International Journal of Pharmaceutical Sciences and Research*, 1(9), 139–143.. 2010.
2. Amdekar, S., Roy, P., Singh, V., et al.. Anti-inflammatory activity of *Lactobacillus* on carrageenan-induced paw edema in male Wistar rats. *International Journal of Inflammation*, 2012, Article ID 752015.. 2012.
3. Asif, M., & Kumar, A.. Acute toxicity study and in-vivo anti-inflammatory activity of different fractions of *Curculigo orchioidea* Gaertn. rhizome in albino Wistar rats. *Iranian Journal of Pharmaceutical Sciences*, 6(2), 125–132.. 2010.
4. Chakote VR, Dhembre GN, Rajguru JR, Joshi DA. In-Situ Gel for Nasal Drug Delivery. *International Journal of Development Research*. 2018;8(2):18763–18769.
5. Deore, S., & Khadabadi, S.. Anti-inflammatory and antioxidant activity of *Chlorophytum borivilianum* root extracts. *Asian Journal of Chemistry*, 20(2), 983–986.. 2008.
6. Dhamale GR, Shinde PB, Rajguru JR. A Review: Gastroretentive Drug Delivery Systems. *International Journal of Pharmaceutical Sciences*. pp.1825–1840. doi:10.5281/zenodo.12818744.
7. Doke R, Rajguru J, Vinchurkar K. Personalized Medicine Through AI-Driven Imaging. In: *Springer Nature*. doi:10.1007/978-3-032-02963-8_7.
8. *Frontiers in Cell and Developmental Biology*. Radical scavenging activity of *Chlorophytum borivilianum* root extract and its protective role in sperm integrity after gamma irradiation. *Front. Cell Dev. Biol.*, 11, 1064574.. 2023.
9. *Frontiers in Immunology*. Anti-nociceptive and anti-inflammatory activities of Asparacosin A involve selective COX-2 and inflammatory cytokines inhibition: an in-vivo and in-silico approach. *Frontiers in Immunology*, 10, 581.. 2019.
10. *Frontiers in Pharmacology*. Andrographolide, a natural anti-inflammatory agent: an update. *Frontiers in Pharmacology*, 13, 878695.. 2022.
11. Furman, D., Campisi, J., Verdin, E., et al.. Chronic inflammation in the etiology of disease across the life span. *Nature Medicine*, 25(12), 1822–1832.. 2019.



12. Gadekar SN, Rajguru JR, Biyani KR. Review on Solid Dispersion for Suitable Drug. *World Journal of Pharmaceutical Sciences*. 2021;9(9):230–235.
13. Gawai NM, Jadhav RR, Modak A, Sawarkar HS, Rajguru JR. Advancements in Nanogel Technology for Drug Delivery: Current Innovations and Future Perspectives. *African Journal of Biomedical Research*. 2024;27(3S):3200–3212. doi:10.53555/AJBR.v27i3S.2905.
14. Gawari PB, Rajguru JR. Confronting the Nipah Virus: Critical Insights and Practical Recommendations. *International Journal of Creative Research Thoughts (IJCRT)*. 2026;14(2). ISSN: 2320-2882.
15. Hegde, S., & Kulkarni, S.. Phytochemical and pharmacological properties of *Curculigo orchioides*: a comprehensive review. *Journal of Health and Allied Sciences NU*, 13(3), 153–160.. 2022.
16. Hegde, S., et al.. *Curculigo orchioides*: an overview of its effects on human health. *Journal of Health and Allied Sciences NU*, 13(3), 153–160.. 2022.
17. Hussain, A., et al.. Evaluation of *Curculigo orchioides* rhizome for mast cell stabilizing and antihistaminic activity. *Journal of Advanced Pharmaceutical Technology & Research*, 3(1), 36–41 (mechanistic support for *Curculigo*).. 2012.
18. Ingole RD, Gawai NM, Rajguru JR. Nanoformulation of Vitamin D Derivatives and Metabolites. *African Journal of Biomedical Research*. 2024;27(4S). doi:10.53555/AJBR.v27i4S.4897.
19. Iqbal, J., & Khan, N.. Review on phytochemical constituents and biological activities of *Chlorophytum orchidastrum*. *Pharmacognosy Reviews*, 15(29), 156–162.. 2021.
20. J Rajguru R. Development and Validation of RP-HPLC and UV Spectrophotometric Absorptivity Method for Simultaneous Estimation of Cyclobenzaprine Hydrochloride and Aceclofenac in Pharmaceutical Dosage Form. *International Journal of Science & Engineering Development Research*. 2020;5(4):320–329.
21. Jaggi, R. K., Jain, V., & Singh, B.. Anti-inflammatory activity of *Stellaria media* (Linn.) extract in acute and chronic animal models of inflammation. *Journal of Ethnopharmacology*, 68(1-3), 273–278 (for methodology reference to carrageenan model).. 2005.
22. Jeevan Rajguru R. Magnetic and pH Sensitive Nanoparticles for Cancer Drug Delivery. *Asian Journal of Pharmaceutical Research and Development*. 2019;7(4).
23. Joshi, T., Sah, S. P., & Singh, A.. Antistress activity of ethanolic extract of *Asparagus racemosus* Willd roots in mice. *Indian Journal of Experimental Biology*, 50(6), 419–424 (for adaptogenic context).. 2012.
24. JR. Rajguru Biomarkers and Diagnostics. *International Journal of Scientific Development and Research*. 2020;5(4).
25. JR. Rajguru Development and Evaluation of Nasal Mucoadhesive In-Situ Gel Formulations of Carbamazepine Using In-Vitro, Ex-Vivo and In-Vivo Methods. *International Research Journal of Pharmacy and Medical Sciences*. 2018;1(6).
26. Kanwar, A. S., & Bhutani, K. K.. Effects of *Chlorophytum arundinaceum*, *Asparagus adscendens* and *Asparagus racemosus* on pro-inflammatory cytokine and corticosterone levels produced by stress. *Phytotherapy Research*, 24(10), 1562–1566.. 2010.
27. Kumar, R., & Arya, V.. Antioxidant and anti-inflammatory properties of *Asparagus adscendens* Roxb. : a review. *Journal of Pharmacy Research*, 10(3), 123–130.. 2016.
28. Kushwah P, Rajguru JR, Jain G, Patidar A, Tomar PS. A Review of Classic Cures for Contemporary Marvels: Unveiling the Medicinal Secrets of *Piper betle* Linn. Leaves and *Nyctanthes arbor-tristis*. *International Journal of Creative Research Thoughts (IJCRT)*. 2024;12(1)–D747.
29. Lande, A. A., Ambavade, S. D., Swami, U. S., et al.. Saponins isolated from roots of *Chlorophytum borivilianum* reduce acute and chronic inflammation and histone deacetylase. *Journal of Integrative Medicine*, 13(1), 25–33.. 2015.
30. Panda, S. K., Das, D., & Tripathy, N. K.. Anti-inflammatory potential of *Chlorophytum borivilianum* Sant. and Fern. root tubers. *Journal of Global Trends in Pharmaceutical Sciences*, 2(3), 242–251.. 2011.



31. Patel, D. K., Kumar, R., Laloo, D., & Hemalatha, S.. Pharmacological and phytochemical review on *Curculigo orchoides* Gaertn. *Asian Pacific Journal of Tropical Biomedicine*, 2(3), 244–249.. 2012.
32. Puri, S., & Ambavade, S.. Anti-inflammatory, anti-arthritis and analgesic activity of ethanol fractions of saponin isolated from roots of *Chlorophytum borivilianum* Sant. and Fern. *Journal of Integrative Medicine*, 16(3), 219–226.. 2018.
33. R Rajguru J. Gene Therapy – Challenges & Success. *International Journal of Trend in Scientific Research and Development*. 2020;4(3).
34. Rajguru JR, Gawari PB, Desai RS, Isal AA. Overview of Intrauterine Drug Delivery System. *International Journal of Creative Research Thoughts (IJCRT)*. 2024;12(1)–D316.
35. Rajguru JR, Navghare AB, Shinde SP, Pawar PP, Lokhande PB. An Overview of Implantable Drug Delivery Systems. *International Journal of Creative Research Thoughts (IJCRT)*. 2024;12(1)–F958.
36. Rajguru JR, Shinde PB, Shinde SP, Humbe KA, Pawar PP. Nasal Routes of Drug Delivery: A Creative Approach. *International Journal of Creative Research Thoughts (IJCRT)*. 2024;12(1)–E477.
37. Rajguru JR, Shirsat MK. Development of the Formulation and Evaluation of the Anti-Arthritic Activity of *Vitex negundo* Gel and Latex. *International Journal of Drug Delivery Technology*. 2023;13(1).
38. Rajguru JR, Shirsat MK. Development of the Formulation and Evaluation of the Anti-Inflammatory Activity of *Vitex negundo* Gel and Latex. *International Journal of Pharmaceutical Quality Assurance*. 2023;14(1).
39. Rajguru JR. A Review on: Mucormycosis. *International Journal of Innovative Research in Technology*. 2021;8(1):323–330.
40. Rajguru JR. Novel Drug Delivery System in Recent Trends as Carrier. *World Journal of Pharmacy and Pharmaceutical Sciences*. 2020;9(5):193–205. doi:10.20959/wjpps20205-15995.
41. Rajput, R., & Singh, M.. Anti-inflammatory potential of saponin-rich fractions from *Curculigo orchoides* in animal models. *International Journal of Pharmacology*, 18(1), 45–54.. 2022.
42. Rani, S., et al.. Herbal medicines as adjuvants for COVID-19: an overview of anti-inflammatory and immunomodulatory effects. *Frontiers in Pharmacology*, 14, 1098742.. 2023.
43. Sethi, J. K., & Pathak, D.. Anti-inflammatory effects of *Chlorophytum tuberosum* Baker: a preclinical study. *Phytomedicine*, 57, 225–232.. 2019.
44. Sharma, S., & Sharma, P.. Phytochemical and pharmacological review of *Chlorophytum borivilianum* Sant. & Fernand. *International Journal of Pharmaceutical Sciences and Research*, 4(7), 2673–2680.. 2013.
45. Singh, A., Malhotra, S., & Subban, R.. Anti-inflammatory and analgesic agents from Indian medicinal plants. *International Journal of Integrative Biology*, 3(1), 57–72.. 2007.
46. Sitaphale GR, Tathe PR, Laddha PR, Charhate KB, Rajguru JR. Phytochemical Screening, Isolation, and Characterization of Extract from Various Parts of *Phoenix sylvestris*. *African Journal of Biomedical Research*. 2024;27(3S):3368–3374. doi:10.53555/AJBR.v27i3S.2938.
47. Tathe PR, Laddha PR, Sitaphale GR, Charhate KB, Pimple UA, Jadhao YD, Alhat RM, Rajguru JR. Studies in Preparation and Evaluation of Nanoparticles for Controlled Drug Delivery of Peptide-Based Drugs. *African Journal of Biomedical Research*. 2024;27(3S):3179–3190. doi:10.53555/AJBR.v27i3S.2894.
48. The Ayurvedic Pharmacopoeia of India, Part I, Vol. IV. Government of India, Ministry of Health and Family Welfare, Dept. of AYUSH. (Monographs on *Curculigo orchoides* and *Chlorophytum borivilianum*).. 2004.
49. Verma, P., & Sharma, R.. Ayurvedic management of Shotha (edema): clinical review and perspectives. *World Journal of Pharmaceutical Research*, 11(13), 318–330.. 2022.
50. Verma, P., & Sharma, R.. Ayurvedic management of Shotha w. s.r. to edema. *World Journal of Pharmaceutical Research*, 11(13), 318–330.. 2022.
51. Wayal SR, Barke SA, Darekar SM, Jalindar AS, Gawai NM, Wankhede HR, Bathe RS, Rajguru JR. Development of Currant-Loaded Nanoparticles and Phytosomes for Enhanced Antioxidant Delivery. *International Journal of Environmental Sciences*. 2025;11(22S):4067–4071. doi:10.64252/p2tec31.



52. Wayal SR, Darekar SM, Jalindar AS, Motr PR, Gawai NM, Bodake PL, Barke SA, Dongare AB, Rajguru JR. Development of a Validated HPTLC Method for the Simultaneous Estimation of Curcumin and Berberine in Dashamoola Kvatha. *International Journal of Environmental Sciences*. doi:10.64252/kq9rtn45.
53. Wayal SR, Rajguru JR, Bhise MR. A Systematic Review on the Effective Teaching Strategies and Methods for Cancer Patient Education. *Journal of Cancer Education*. 2025. doi:10.1007/s13187-025-02759-z.
54. Winter, C. A., Risley, E. A., & Nuss, G. W.. Carrageenin-induced edema in hind paw of the rat as an assay for antiinflammatory drugs. *Proceedings of the Society for Experimental Biology and Medicine*, 111(3), 544–547 (original model description).. 1962.
55. Yadav, S. P., & Singh, R.. Ethnobotanical and pharmacological significance of *Chlorophytum arundinaceum* Baker. *Journal of Ethnopharmacology*, 251, 112484.. 2020

